InflaRx (IFRX) Net Margin Growth (1y) (2019 - 2026)
InflaRx (IFRX) Net Margin Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -185.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -763.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 529.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4,168.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 673.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2,208.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -1,652.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 29,636.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -392.00 |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | -886.00 |
| Sep 30, 2025 | -3.74 Mn |
| Jun 30, 2025 | 18.12 Mn |
| Mar 31, 2025 | 372,731.00 |
| Dec 31, 2024 | 11,038.00 |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -21.83 Mn |
| Mar 31, 2024 | 19.66 Mn |
| Dec 31, 2023 | -686,933.00 |
| Sep 30, 2023 | -118,996.00 |
| Jun 30, 2023 | 40,562.00 |
| Mar 31, 2023 | -22.49 Mn |
| Dec 31, 2022 | -60.20 Mn |
| Sep 30, 2022 | -61,435.00 |
| Jun 30, 2022 | -1,774.00 |
| Mar 31, 2022 | 137,913.00 |
| Dec 31, 2021 | 30.65 Mn |
| Sep 30, 2021 | 395,343.00 |
| Jun 30, 2021 | -155,044.00 |